

#19/H
Harry
Patent
Attorney's Docket No. 032751-015
1-12-01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

In re Patent Application of

Jean-Marc BALLOUL et al.

Application No.: 09/043,933

Filed: March 30, 1998

For: PHARMACEUTICAL COMPOSITION
FOR TREATING PAPILLOMAVIRUS
TUMORS AND INFECTION

Group Art Unit: 1648

Examiner: S. Foley

JAN 10 2001

TECH CENTER 16

8B15

AMENDMENT/REPLY TRANSMITTAL LETTER

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Enclosed is a reply for the above-identified patent application.

☐ A Petition for Extension of Time is also enclosed.

☐ A Terminal Disclaimer and a check for ☐ \$55.00 (248) ☐ \$110.00 (148) to cover the requisite Government fee are also enclosed.

☐ Also enclosed is _____

☐ Small entity status is hereby claimed.

☐ Applicant(s) request continued examination under 37 C.F.R. § 1.114 and enclose the ☐ \$355.00 (279) ☐ \$710.00 (179) fee due under 37 C.F.R. § 1.17(e).

☐ Applicant(s) previously submitted ___, on ___, for which continued examination is requested.

☐ A Request for Entry and Consideration of Submission under 37 C.F.R. § 1.129(a) (146/246) is also enclosed.

☐ No additional claim fee is required.

RECEIVED

JAN 10 2001

Amendment/Reply Transmittal Letter

Application No. 09/043,933

Attorney's Docket No. 032751-015

TECH CENTER 1E

Page 2

[x] An additional claim fee is required, and is calculated as shown below:

AMENDED CLAIMS					
	NO. OF CLAIMS	HIGHEST NO. OF CLAIMS PREVIOUSLY PAID FOR	EXTRA CLAIMS	RATE	ADD'T'L FEE
Total Claims	77	MINUS 36=	41	× \$18.00 (103) =	\$738.00
Independent Claims	5	MINUS 3=	2	× \$80.00 (102) =	\$160.00
If Amendment adds multiple dependent claims, add \$270.00 (104)					
Total Amendment Fee					\$898.00
If small entity status is claimed, subtract 50% of Total Amendment Fee					
TOTAL ADDITIONAL FEE DUE FOR THIS AMENDMENT					\$898.00

[] A claim fee in the amount of \$_____ is enclosed.


[x] Charge \$ \$898.00 to Deposit Account No. 02-4800.

The Commissioner is hereby authorized to charge any appropriate fees under 37 C.F.R. §§ 1.16, 1.17, 1.20(d) and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 02-4800. This paper is submitted in duplicate.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

By:


Teresa Stanek Rea
Registration No. 30,427

P.O. Box 1404
Alexandria, Virginia 22313-1404
(703) 836-6620

Date: January 8, 2001

(10/00)

#19/H

Patent
Attorney's Docket No. 032751-015

Harry
1-12-01
RECEIVED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



In re Patent Application of
Jean-Marc BALLOUL et al.

Group Art Unit: 1648

Application No.: 09/043,933

Examiner: S. Foley

Filed: March 30, 1998

For: PHARMACEUTICAL COMPOSITION
FOR TREATING PAPILLOMAVIRUS
TUMORS AND INFECTION

TECH CENTER

JAN 10 2001

AMENDMENT & REPLY

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to the Office Action dated October 6, 2000, kindly amend the
application as follows:

01/16/2001 DWILLIA1 00000004 024800 09043933

01 FC:102 80.00 CH
02 FC:103 11.30 CH

IN THE CLAIMS:

Please cancel claims 1-9, 21, 23, 24 and 32-37 without prejudice or disclaimer to
the subject matter recited therein.

Kindly add new claims 38-78

38. A pharmaceutical composition intended for the treatment or prevention of a
papillomavirus infection or tumor, which comprises as therapeutic agents at least one
polypeptide from the early region of a human papillomavirus and at least one polypeptide

H
Sub
I 1